2 results
Not approvedWill not start
The primary objective of this study is to demonstrate that the IOP-lowering efficacy of Travoprost Ophthalmic Solution, 0.004% (preserved with POLYQUAD) is noninferior to Timolol Ophthalmic Solution (0.5% or 0.25%) in pediatric glaucoma patients.
Approved WMOPending
Main objective: Part A: To evaluate the safety and tolerability of AL102 in subjects withprogressing desmoid tumorsPart B: To evaluate effects of AL102 on disease progression in subjectswith progressing desmoid tumorsOLE: To evaluate the safety and…